Journal of the American Heart Association, Volume 15, Issue 6 , March 17, 2026. BackgroundIn symptomatic patients with treatment‐refractory obstructive hypertrophic cardiomyopathy, septal reduction therapy (SRT) is recommended to relieve obstruction.
This study examined the challenges associated with SRT access in the United States.MethodsCross‐sectional study of commercially insured individuals or Medicare Advantage with Part D members captured in the Optum Research Database from May 2012 to April 2022. Patients with obstructive hypertrophic cardiomyopathy who underwent SRT were identified based on diagnosis/procedure codes.
Treatment center procedural volume was defined based on tertiles. SRT access was assessed by the distance patients traveled to care and the proportion of patients treated at hypertrophic cardiomyopathy centers of excellence (COE) by region.
Cohorts of patients with coronary artery disease who underwent percutaneous coronary intervention or coronary artery bypass grafting were compared with the SRT cohort.ResultsOverall, 1864 patients who underwent SRT, 235 652 with percutaneous coronary intervention, and 69 236 with coronary artery bypass grafting were included. In the SRT cohort, 368 patients (19.7%) underwent procedures at COE.
Journal of the American Heart Association published a clinical update in Cardiology on 10 Mar 2026.
The item focuses on Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy.
Review the original article for the full source wording and details.